secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0000950103-24-002027
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead to acquire CymaBay for $4.3B, adding seladelpar for PBC with FDA priority review
--------------------------------------------------------------------------------

- Gilead to pay $32.50/share in cash, total equity value of $4.3 billion, a 27% premium over CymaBay's Feb 9 close.
- Seladelpar (PPARδ agonist) for primary biliary cholangitis has FDA priority review; PDUFA date Aug 14, 2024.
- Phase 3 RESPONSE trial: seladelpar achieved primary composite endpoint (61.7% biochemical response vs 20% placebo).
- Deal expected to close in Q1 2024, subject to HSR clearance and majority tender; termination fee of $151.6M.
- Upon FDA approval, transaction expected to be ~neutral to Gilead EPS in 2025 and significantly accretive thereafter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/0000950103-24-002027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000095010324002027/dp206638_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-002027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer